Predicting Early or Late Mortality in Multiple Myeloma?

Would you want to know if your myeloma was likely to result in early vs late mortality?  I would like to know. What’s your feeling about this?

Multiple myeloma flame shaped plasma cell
Multiple myeloma flame shaped plasma cell (UVA photo)

Gene Variants Can Predict Early or Late Mortality in Multiple Myeloma
Elsevier Global Medical News. 2008 Nov 11, MG Sullivan

Genetic variants in the DNA of patients with multiple myeloma appear to strongly influence survival, a groundbreaking new genomic study has concluded.

In this first pass at identifying genetic markers for survival, treatment response, and complications in the disease, a group of 3,400 variants predicted early or late mortality 76% of the time, Dr. Brian Van Ness said in an interview about the initial report (BMC Medicine 2008 Sept. 8 [doi: 10.1186/1741-7015-6-26]).

“Clearly, inherited genetics influenced survival,” said Dr. Van Ness
of the University of Minnesota, Minneapolis. “What we have not yet done is identify which specific variants are responsible for these differences. Our hypothesis is that it won’t be a single variant driving response or survival, but a complex interaction of many.”

After narrowing down the initial 3,404 candidate single nucleotide polymorphisms (SNPs), Dr. Van Ness and his colleagues are now focusing on 1,000 SNPs found to be most strongly associated with the outcome
measures. More studies are on the way using this genetic panel, he said.

Indeed, just 2 weeks after the first study appeared, a coinvestigator, Dr. Gareth Morgan of London’s Royal Marsden Hospital, published findings on the association between certain SNPs and the incidence of
treatment-associated venous thromboembolism (VTE). The analysis showed that some of the variants associated with thalidomide-related VTE occurred in pathways important in drug transport and metabolism.

“The effects of the SNPs associated with thalidomide-related VTE may be functional at the level of the tumor cell, the tumor-related microenvironment, and the endothelium,” Dr. Morgan and his colleagues wrote (Blood 2008 Sept. 19 [Epub ahead of print]).

“Another study, currently submitted, has identified an association between some of the variants and the development of severe myeloma bone disease,” Dr. Van Ness said.

The initial investigation used a genetic screen developed from two DNA data sets: cells from the Coriell Institute for Medical Research, and samples obtained from multiple myeloma patients enrolled in two
randomized drug trials, as well as some unaffected spouses. The samples came from white, black, Hispanic, and Asian patients from North America and Europe. The candidate SNPs, occurring on 983 genes, were chosen based on the most recent genetic research and included on a myeloma-specific gene-testing chip.

The investigators chose extremes of survival as the first test of the panel, because this comparison was most likely to show the effects of any genetic variant. “We took the worst outcomes – people who died in
the first year of their disease – and the best outcomes – those who survived at least 3 years without progression,” Dr. Van Ness said. After repeatedly running the screen on both data sets, the team concluded that, as a whole, it discriminated the survival groups correctly 76% of the time.

Further drilling down identified several SNPs of particular interest, including some associated with drug metabolism, transport, and export; a variant that induces myeloma apoptosis; one associated with cellular
migration and angiogenesis; and several linked to proliferative responses.

Although not designed to detect racial differences, the initial screen did identify some interesting variations: 401 of the SNP variants occurred only in black patients. In whites, there was no difference in these SNPs between cases and controls.

“We know that African Americans have a two- to threefold increase in the incidence of myeloma, but we don’t yet know why,” Dr. Van Ness said. “We’ll be trying to identify those genetic variants that might uniquely increase the risk for one race to develop myeloma over another.”

Neither this initial analysis nor subsequent ones will examine the possible interplay of environment with genetics. But, Dr. Van Ness said, such studies may be forthcoming. The International Myeloma Foundation of North Hollywood, Calif., is conducting a patient survey to begin assessing what role – if any – environmental exposure plays in disease development. The 36-page survey asks patients to detail their environmental, dietary, and geographical exposures. The National Cancer Institute will collaborate with the group in evaluating the data.

The International Myeloma Foundation is also the curator of the DNA samples used in the analysis through its Bank on a Cure program. “Bank on a Cure was developed by an international group of physicians and scientists to deal with a disease that’s difficult to deal with,” Dr. Van Ness said. “It’s not a high-incidence cancer, so it’s not easy to research.”

The Bank on a Cure group developed cooperative agreements with national and international clinical trial groups, and the studies were funded by the International Myeloma Foundation. While exploration of genetic variants relevant to multiple myeloma is in its infancy, Dr. Van Ness predicted the effect could be profound.

“It’s already fairly well established that the genetics of the tumor cells themselves impact response and survival,” he said. “But beyond this is the impact of every individual patient’s genetics – how they absorb, distribute, metabolize, and export drugs, even what race they are. If we understand why someone doesn’t respond to a drug, we could better target their therapy. If we could predict which patient might develop a life-threatening blood clot during treatment, we could take steps to prevent it.”
Copyright © 2008 International Medical News Group

Source: http://www.oncologystat.com/news-and-viewpoints/news/Gene_Variants_Can_Predict_Early_or_Late_Mortality_in_Multiple_Myeloma_US.html

6 Comments

  1. John E. Smith

    Oh yeah, I’d like to know. Did you ever have cytogenetic tests performed on any of your biopsies? My oncologist ordered one first thing. Evidently, there were no abnormalities in my sample, that is, no missing chromosomes or ones that had traded places.

  2. Beth

    Hi John,

    I did have the cytogenetic tests done. Over time there have been some mutations. In 2007, I saw this on my report:

    The result is abnormal and indicates a plasma cell clone with an IGH gene rearrangement and monosomy 13. In addition, approximately 50% of plasma cells had a tetraploid version of this clone. An abnormal tetraploid clone is reportedly associated with an unfavorable prognosis in multiple myeloma.
    Reference: Fonseca et al., Blood 99:3735-3741, 2002.

    BUT I wrote to Dr. Fonseca to ask about this and his reply was:

    “There is little information regarding the tetraploidy as prognostic marker. The fact that you have avoided SCT for 4 years already is in it of itself a very good prognostic sign.”

    I haven’t had another BMB since before the SCT, and nobody really sees a reason for me to bother unless it’s required for a trial.

  3. John E. Smith

    Ya, my current oncologist is not a big fan of BMBs either for maintenance diagnostics. He watches the SPEP, CBC, and organ function labs. I guess early on hematologists just throw the diagnostic book at their patients. (As long as you have insurance!)

    Glad you are stable and feeling well.

  4. David Emerson

    Gene testing for mm survivors will provide a great deal of useful information and having a genetic variant indicates a predisposition only- not a certainty.

    Gene variants can predict which therapies might be most effective for you-

    http://beating- myeloma.org /article/myeloma-issues/individualizing-treatment-for-multiple-myeloma-patients

    “Dr Roses has a formidable reputation in the field of “pharmacogenomics” – the application of human genetics to drug development – and his comments can be seen as an attempt to make the industry realize that its future rests on being able to target drugs to a smaller number of patients with specific genes.”

    http://beating- myeloma.org /article/general-mm/glaxo-chief-our-drugs-do-not-work-on-most-patients

  5. Patricia

    Hi Beth,

    Very, very interesting development. I discussed it with my myelomic husband David, his response to being tested “No way…what would be the point”. I have to agree with him. If he received a result indicating a poorer prognosis, it would definitely suck all of the hope out of our lives. That hope is very important to us.

    Interestingly, I’ve just had genetic testing done myself (I was diagnosed this August at age 46 with invasive ductal breast cancer) and was found to be positive for a deleterious deletion on the BRCA2 (BReast CAncer) gene, which statistically puts me a very high chance of relapse or development of ovarian ca . Fortunately there is something I can do to greatly reduce my risk : have a bilateral mastectomy and salpino-oophorectomy/hysterectomy. I start this process in a few weeks. I had the gene testing done precisely because there is something I could do with the results (in addition to knowing my childrens’ risk), other than just increased surveillance or taking stronger adjuvant therapy/chemo.

    Just my 2 cents.

    Thank you so much for all you do for the myeloma community.

    Patricia, St. John’s, FL

  6. unco

    Being stable is a good thing! Do you have your day +90 test results?

Comments are closed.